Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for GeneDx Holdings (WGS) over the last 5 years, with Q3 2025 value amounting to $29000.0.

  • GeneDx Holdings' Asset Writedowns and Impairment changed N/A to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $72000.0, marking a year-over-year increase of 8000.0%. This contributed to the annual value of $180000.0 for FY2024, which is 9826.96% down from last year.
  • GeneDx Holdings' Asset Writedowns and Impairment amounted to $29000.0 in Q3 2025.
  • In the past 5 years, GeneDx Holdings' Asset Writedowns and Impairment ranged from a high of $209.4 million in Q4 2022 and a low of -$1.3 million during Q3 2021
  • In the last 5 years, GeneDx Holdings' Asset Writedowns and Impairment had a median value of $645000.0 in 2021 and averaged $20.2 million.
  • As far as peak fluctuations go, GeneDx Holdings' Asset Writedowns and Impairment surged by 2069572.99% in 2022, and later tumbled by 9811.32% in 2024.
  • Quarter analysis of 5 years shows GeneDx Holdings' Asset Writedowns and Impairment stood at $1.0 million in 2021, then skyrocketed by 20695.73% to $209.4 million in 2022, then tumbled by 96.05% to $8.3 million in 2023, then crashed by 99.48% to $43000.0 in 2024, then tumbled by 32.56% to $29000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $29000.0 for Q3 2025, versus $43000.0 for Q4 2024 and $40000.0 for Q1 2024.